





















36. Lin CI, Yu HH, Lee JH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. *Clin Rheumatol*. 2012; 31: 1223-30.
37. Stephan JL, Kone-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. *Rheumatology (Oxford)*. 2001; 40: 1285-92.
38. Kounami S, Yoshiyama M, Nakayama K, et al. Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. *Acta Haematol*. 2005; 113: 124-9.
39. Larroche C, Bruneel F, Andre MH, et al. Intravenously administered gamma-globulins in reactive hemophagocytic syndrome. *Ann Med Interne*. 2000; 151: 533-9.
40. Emmenegger U, Frey U, Reimers A, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. *Am J Hematol*. 2001; 68: 4-10.
41. Torres Jiménez A, Solís Vallejo E, Zeferino Cruz M. Macrophage activation syndrome as the initial manifestation of severe juvenile onset systemic lupus erythematosus. Favorable response to cyclophosphamide. *Reumatol Clin*. 2014; 10: 331-5.
42. Grom AA. Natural killer cell dysfunction: A common pathway in systemic-onset juvenile arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? *Arthritis Rheum*. 2004; 50: 689-98.
43. Ogilvie EM, Fife MS, Thompson SD, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. *Arthritis Rheum*. 2003; 48: 3202-6.
44. Saurenmann RK, Rose JB, Tyrrell, et al. Epidemiology of juvenile idiopathic arthritis in a multicenter cohort: ethnicity as a risk factor. *Arthritis Rheum*. 2007; 56: 1974-84.
45. Ravelli A. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *RMD Open* 2016; 2: e000161.
46. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. *J Interferon Cytokine Res*. 2002; 22: 913-22.
47. Stephan JL, Kone-Paut I, Galambrun C, et al. Reactive Haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. *Rheumatology (Oxford)*. 2001; 40: 1285-92.
48. Grom AA. NK dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis. *Arthritis Rheum*. 2004; 50: 689-98.
49. Mattunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. *Rheumatology (Oxford)*. 2011; 50: 417-9.
50. ClinicalTrials.gov. Ong-term Follow-up of HLH Patients Who Received Treatment With NI-050, an Anti-interferon Gamma Monoclonal Antibody. NLM Identifier: NCT02069899. Available from: <http://clinicaltrials.gov/show/NCT02069899> Accessed: 12 Apr 2015.
51. Ruscitti P, Cipriani P, Benedetto PD, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? *Expert Rev Clin Immunol*. 2017; 13: 1041-7.

Non-commercial use only